Document Type
Patent
Publication Date
3-15-2016
Patent Number
9283241
CPC
A61L 27/227 (20130101); A61L 27/24 (20130101); A61L 27/3633 (20130101); A61L 27/3683 (20130101); A61L 27/3687 (20130101); A61L 27/50 (20130101); A61L 27/54 (20130101); A61K 31/7034 (20130101); A61F 2/24 (20130101); A61F 2/82 (20130101); A61L 27/507 (20130101); A61K 31/7024 (20130101); A61K 31/7032 (20130101); A61L 2300/216 (20130101); A61L 2400/18 (20130101); A61L 2430/20 (20130101)
Abstract
Disclosed is a medical device treated with a phenolic compound and a process for treating a device with the phenolic compound. For example, a collagen or elastin-based scaffold can be treated with pentagalloyl glucose (PGG). The treated scaffold can become resistant to glycoxidative stress associated with advanced glycation end products (AGEs) that are present in a hyperglycemic environments associated with diabetes mellitus. The treated scaffold can exhibit a reduced increase in stiffness as compared to an untreated scaffold. The treated scaffold can also exhibit reduced inflammation without negatively affecting the ability of the scaffold to remodel in vivo.
Application Number
13/938,275
Assignees
Clemson University, Clemson, SC (US)
Filing Date
07/10/2013
Primary/U.S. Class
1/1
Other/U.S. Class
A61F 2/06 (20130101); A61F 2/82 (20130101); A61L 27/22 (20060101); A61L 27/24 (20060101); A61L 27/36 (20060101); A61L 27/50 (20060101); A61L 27/54 (20060101); A61K 31/7032 (20060101); A61K 31/7034 (20060101); A61K 31/7024 (20060101); A61F 2/24 (20060101)